CONCLUSIONS
inflammation, neutrophilic, exacerbations, COPD
ADVERSE REACTIONS, COPD, INFLAMMATION
According to the findings of a 6‐month follow‐up study, doxofylline, when used as an adjuvant drug, displays a favorable therapeutic effect on COPD patients with neutrophilic and eosinophilic clinical subtypes. It is capable of minimizing severe acute exacerbations, and in the case of neutrophilic subtypes, a consistent reduction in the number of exacerbations was observed after 3 months of use, whereas eosinophilic subtypes displayed a consistent reduction in exacerbations after 6 months, although further long‐term studies may be necessary to establish a concrete causal relationship. In addition, doxofylline can reduce reliance on glucocorticoids and promote long‐term reduction of inflammation (after at least 3 months of usage). Moreover, the incidence of adverse reactions associated with its use is low, making it a safe choice for clinical treatment.